{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:06:27Z","timestamp":1791389187151,"version":"4.3.3"},"reference-count":38,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011421","name":"Sanofi China Investment Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011421","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.clinthera.2025.06.011","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T03:57:43Z","timestamp":1753156663000},"page":"746-753","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost-Effectiveness of Antiarrhythmic Drugs for Treating Paroxysmal or Persistent Atrial Fibrillation in China: An Economic Evaluation"],"prefix":"10.1016","volume":"47","author":[{"given":"Fuming","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dunming","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junling","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3470-0748","authenticated-orcid":false,"given":"Yingyao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.06.011_bib0001","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.jacc.2020.02.025","article-title":"Atrial fibrillation: JACC council perspectives","volume":"75","author":"Chung","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0002","first-page":"1332","article-title":"Risk of hospital admissions in patients with atrial fibrillation: a systematic review and meta-analysis","volume":"35","author":"Meyre","year":"2019","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0003","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0004","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","article-title":"Early rhythm-control therapy in patients with atrial fibrillation","volume":"383","author":"Kirchhof","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0005","doi-asserted-by":"crossref","first-page":"n991","DOI":"10.1136\/bmj.n991","article-title":"Treatment timing and the effects of rhythm control strategy in patients with atrial fibrillation: nationwide cohort study","volume":"373","author":"Kim","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0006","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.jacc.2022.03.337","article-title":"The increasing role of rhythm control in patients with atrial fibrillation: JACC State-of-the-art review","volume":"79","author":"Camm","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0007","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1161\/CIRCULATIONAHA.111.019927","article-title":"Antiarrhythmic drug therapy for atrial fibrillation","volume":"125","author":"Zimetbaum","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0008","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1161\/CIR.0b013e3181fa3cf4","article-title":"2011 ACCF\/AHA\/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"123","author":"Wann","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0009","first-page":"572","article-title":"Chinese Society of Cardiology, Chinese Medical Association; Heart Rhythm Committee of Chinese Society of Biomedical Engineering","volume":"51","author":"Xin","year":"2023","journal-title":"Chinese guidelines on diagnosis and management of atrial fibrillation"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0010","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1161\/CIRCULATIONAHA.118.035455","article-title":"Modernized classification of cardiac antiarrhythmic drugs","volume":"138","author":"Lei","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0011","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1540-8167.2010.01764.x","article-title":"A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study","volume":"21","author":"Le Heuzey","year":"2010","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0012","article-title":"Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation","volume":"9","author":"Valembois","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0013","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/europace\/eur194","article-title":"The cost of illness of atrial fibrillation: a systematic review of the recent literature","volume":"13","author":"Wolowacz","year":"2011","journal-title":"Europace"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0014","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.vhri.2013.02.008","article-title":"Economic burden of individual suffering from atrial fibrillation-related stroke in China","volume":"2","author":"Hu","year":"2013","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0015","series-title":"China Guidelines for Pharmacoeconomic Evaluations","author":"Liu","year":"2020"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0016","series-title":"China Statistics Yearbook 2022","year":"2022"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0017","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II Good Practices Task Force","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0018","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020968","article-title":"Rationale and design of the improving Care for Cardiovascular Disease in China (CCC) project: a national registry to improve management of atrial fibrillation","volume":"8","author":"Hao","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0019","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1056\/NEJMoa0803778","article-title":"Effect of dronedarone on cardiovascular events in atrial fibrillation","volume":"360","author":"Hohnloser","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0020","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.clinthera.2012.06.007","article-title":"Cost-effectiveness of dronedarone in atrial fibrillation: results for Canada, Italy, Sweden, and Switzerland","volume":"34","author":"\u00c5kerborg","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0021","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10198-012-0391-x","article-title":"Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation\u2014results for Canada, Italy, Sweden and Switzerland","volume":"14","author":"Nilsson","year":"2013","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0022","series-title":"China Population Census Yearbook 2020","year":"2022"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0023","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ehj.2003.12.012","article-title":"Decreasing one-year mortality and hospitalization rates for heart failure in Sweden; data from the Swedish Hospital Discharge Registry 1988 to 2000","volume":"25","author":"Schaufelberger","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0024","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/eurheartj\/ehn541","article-title":"Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987-2003 from the Swedish Hospital Discharge Registry","volume":"30","author":"Shafazand","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0025","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1161\/01.STR.24.6.796","article-title":"Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project","volume":"24","author":"Dennis","year":"1993","journal-title":"Stroke"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0026","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/europace\/euq450","article-title":"Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation","volume":"13","author":"Freemantle","year":"2011","journal-title":"Europace"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0027","first-page":"890","article-title":"Risk of cardiovascular events, stroke, congestive heart failure, interstitial lung disease, and acute liver injury: dronedarone versus amiodarone and other antiarrhythmics","volume":"6","author":"Gao","year":"2013","journal-title":"J Atr Fibrillation"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0028","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.clinthera.2018.11.008","article-title":"Radiofrequency catheter ablation versus cryoballoon ablation in the treatment of paroxysmal atrial fibrillation: a cost-effectiveness analysis in China","volume":"41","author":"Sun","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0029","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/13696998.2017.1297309","article-title":"Understanding the economic burden of heart failure in China: impact on disease management and resource utilization","volume":"20","author":"Huang","year":"2017","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0030","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jval.2019.02.001","article-title":"Cost-effectiveness of cryoballoon ablation versus radiofrequency ablation for paroxysmal atrial fibrillation in China: results based on real-world data","volume":"22","author":"Ming","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0031","doi-asserted-by":"crossref","first-page":"A338","DOI":"10.1016\/S1098-3015(10)74663-5","article-title":"PCV136 Health state utility values for atrial fibrillation and associated treatment-related adverse events","volume":"12","author":"Doyle","year":"2009","journal-title":"Value in Health"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0032","article-title":"Cost-effectiveness of dronedarone and amiodarone for the treatment of Chinese patients with atrial fibrillation","volume":"9","author":"Zhang","year":"2021","journal-title":"Front Public Health"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0033","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.jval.2021.10.014","article-title":"Long-term cost-effectiveness comparison of catheter ablation and antiarrhythmic drugs in atrial fibrillation treatment using discrete event simulation","volume":"25","author":"Hu","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0034","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1161\/CIRCULATIONAHA.122.058575","article-title":"Cost-effectiveness of catheter ablation versus antiarrhythmic drug therapy in atrial fibrillation: the CABANA randomized clinical trial","volume":"146","author":"Chew","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0035","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jjcc.2014.01.010","article-title":"Complexity of atrial fibrillation patients and management in Chinese ethnicity in routine daily practice: insights from the RealiseAF Taiwanese cohort","volume":"64","author":"Wang","year":"2014","journal-title":"J Cardiol"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0036","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/CEOR.S36019","article-title":"Cost-effectiveness of dronedarone and standard of care compared with standard of care alone: US results of an ATHENA lifetime model","volume":"5","author":"Reynolds","year":"2013","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0037","first-page":"1249","article-title":"Cost-effectiveness of dronedarone in patients with atrial fibrillatikon in the ATHENA trial","volume":"29","author":"Berg","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.clinthera.2025.06.011_bib0038","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joiknt Committee on Clinical Practice Guidelines","volume":"83","author":"Joglar","year":"2024","journal-title":"J Am Coll Cardiol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825002176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825002176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T05:03:51Z","timestamp":1763787831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825002176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0149291825002176"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.06.011","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Antiarrhythmic Drugs for Treating Paroxysmal or Persistent Atrial Fibrillation in China: An Economic Evaluation","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}